Metformin: mechanisms of antihyperglycemic action, other pharmacodynamic properties, and safety perspectives.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
A J Garber

Abstract

To characterize the mechanisms of action of metformin and describe its effects and safety profile. Results of more than 30 years of clinical use in countries other than the United States are summarized. In addition, the pharmacologic properties of metformin are compared with those of other antihyperglycemic agents. Approximately 90% of all cases of diabetes are non-insulin-dependent diabetes mellitus (NIDDM)--a heterogeneous disease that involves several pathogenic factors and is associated with other coexisting conditions, such as cardiovascular disease, hypertension, and obesity. Thus, an agent that controls blood glucose levels and has favorable effects on the concomitant conditions should be considered when pharmacologic intervention is needed for the treatment of NIDDM. Metformin possesses the pharmacodynamic properties to do both. Its mechanisms of action include the reduction of hepatic glucose production and enhancement of peripheral glucose disposal, making metformin an effective antihyperglycemic agent. It also has other pharmacologic properties, independent of its glycemic effects, that offer additional clinical benefits in comparison with other pharmacologic NIDDM treatments. These benefits include stabilization or ...Continue Reading

References

Apr 1, 1979·Diabetologia·E J Coetzee, W P Jackson
Aug 12, 1978·British Medical Journal·U BergmanB E Wiholm
Oct 1, 1992·The Journal of Clinical Investigation·V SarabiaA Klip
Apr 1, 1992·British Journal of Pharmacology·C J BaileyC Day
Jun 1, 1992·Diabetes Care·C J Bailey
May 1, 1991·Diabetic Medicine : a Journal of the British Diabetic Association·P J GrantC R Prentice
Oct 1, 1991·Australian and New Zealand Journal of Medicine·H D McIntyreD P Cameron
Dec 1, 1991·The Journal of Clinical Endocrinology and Metabolism·R A DeFronzoD C Simonson
Apr 1, 1991·Diabetes Care·T L DornanR B Tattersall
Jul 1, 1990·Diabetic Medicine : a Journal of the British Diabetic Association·S Josephkutty, J M Potter
Jun 1, 1990·Diabetes Care·A Klip, L A Leiter
Apr 1, 1989·Diabetic Medicine : a Journal of the British Diabetic Association·O PedersenN Sørensen
Sep 1, 1987·Diabetic Medicine : a Journal of the British Diabetic Association·R R HolmanR C Turner
Oct 1, 1988·Diabetic Medicine : a Journal of the British Diabetic Association·S G RainsR S Elkeles
May 1, 1988·Baillière's Clinical Endocrinology and Metabolism·C J Bailey, M Nattrass
May 1, 1987·Diabetes·R A JacksonA B Kurtz
Oct 1, 1983·The Journal of Clinical Endocrinology and Metabolism·V TrischittaR Vigneri
Aug 31, 1995·The New England Journal of Medicine·M StumvollJ E Gerich
Oct 1, 1994·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·A J KrentzC J Bailey
Jun 1, 1994·Diabetic Medicine : a Journal of the British Diabetic Association·E HellmuthL Mølsted-Pedersen
Nov 1, 1993·General Pharmacology·C J Bailey
Apr 1, 1994·Journal of Internal Medicine·K LandinU Smith
Oct 15, 1993·Biochemical and Biophysical Research Communications·A HamannS Matthaei

❮ Previous
Next ❯

Citations

Jun 8, 2013·Renal Failure·Deniz AvcıAbdulsamet Erden
Oct 12, 2013·Nature Reviews. Drug Discovery·Lorenzo GalluzziGuido Kroemer
Aug 24, 1999·Endocrine Reviews·L PoretskyL C Giudice
Nov 13, 2020·Frontiers in Pharmacology·Guadalupe Del Carmen Baeza-FloresVinicio Granados-Soto

❮ Previous
Next ❯

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.